Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.

Background: Alcohol use disorder (AUD) accounts for millions of acute care encounters annually in the United States. Hospitalization represents a vital opportunity to intervene pharmacologically, but low medication adherence is a significant barrier. Two single-dose, adherence-independent interventions are well suited for pre-discharge administration: intravenous (IV) ketamine and intramuscular (IM) naltrexone.

Adolescent US Poison Center Exposure Calls During the COVID-19 Pandemic.

Purpose: The objective of this study was to evaluate trends and characteristics in adolescent poison center (PC) exposure calls before and during the COVID-19 pandemic.

Methods: A retrospective review of PC calls for adolescents aged 13-17 years from January 1, 2018 through June 30, 2021.

Results: During the pandemic, US PCs had a higher proportion of adolescent exposure calls managed in a healthcare facility (71.